shr2554
Small moleculeexperimental
Clinical trial activity
25 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
15
Phase 3
1
Phase 4
0
Earliest trial started Aug 14, 2018 (NCT03603951)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Hodgkin Disease · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 3
- Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
Mechanism of action
EZH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1c(N(CC)C2CCOCC2)cc2oc(CN3CCCCC3)cc2c1C(=O)NCc1c(C)cc(C)[nH]c1=O- Mol. weight
- 548.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5939817 ↗
Also known as
- shr2554
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07230106 | Phase 2 | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT07175220 | Phase 2 | Oct 9, 2025 | Hengrui Therapeutics, Inc. |
| NCT07125950 | Phase 2 | Sep 30, 2025 | Henan Medical University |
| NCT07102901 | Phase 2 | Sep 5, 2025 | Hengrui Therapeutics, Inc. |
| NCT07294664 | Phase 2 | Jun 15, 2025 | Zhengzhou University |
| NCT06679673 | Phase 2 | Dec 31, 2024 | Fudan University |
| NCT06712173 | Phase 1 | Dec 1, 2024 | China Academy of Chinese Medical Sciences |
| NCT06568094 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2024 | Hengrui Therapeutics, Inc. |
| NCT06368167 | Phase 2 | Apr 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06173999 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Hengrui Therapeutics, Inc. |
| NCT06122389 | Phase 3 | Nov 30, 2023 | Hengrui Therapeutics, Inc. |
| NCT06093945 | Phase 1 | Nov 6, 2023 | Hengrui Therapeutics, Inc. |
| NCT06010680 | Phase 1 | Oct 7, 2023 | Hengrui Therapeutics, Inc. |
| NCT05896046 | Phase 1/Phase 2 (Phase 2) | Jun 14, 2023 | People's Liberation Army of China |
| NCT05661591 | Phase 1 | Jan 4, 2023 | Hengrui Therapeutics, Inc. |
| NCT05592262 | Phase 1 | Nov 15, 2022 | Hengrui Therapeutics, Inc. |
| NCT05559008 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Jiao Tong University |
| NCT05049083 | Phase 1 | Sep 23, 2021 | Hengrui Therapeutics, Inc. |
| NCT04407741 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | People's Liberation Army of China |
| NCT04627129 | Phase 1 | Jun 1, 2020 | Hengrui Therapeutics, Inc. |
Showing 20 of 25 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 17 | 17 | 3 | 2018 |
| Fudan University | Academic/Hospital | 3 | 2 | 1 | 2018 |
| People's Liberation Army of China | Government | 2 | 2 | 1 | 2020 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Zhengzhou University | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1